Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efinaconazole - Kaken Pharmaceutical

Next Previous
Search
Drug Profile

Efinaconazole - Kaken Pharmaceutical

Alternative Names: Clenafin; IDP-108; Jublia; KP-103

Latest Information Update: 10 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kaken Pharmaceutical
  • Developer AIM China; Almirall S.A.; Bausch Health Companies; Dong-A ST; Kaken Pharmaceutical; Main Life Corporation; Tai Tien Pharmaceuticals
  • Class Antifungals; Fluorobenzenes; Piperidines; Small molecules; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Onychomycosis

Most Recent Events

  • 28 Mar 2025 Registered for Onychomycosis (In adolescents, In children, In adults) in Italy (Topical)
  • 24 Feb 2025 Almirall S.A. anticipates national marketing authorizations for efinaconazole in Europe during the first half of 2025
  • 15 Oct 2024 Almirall announces the successful completion of the decentralized regulatory procedure in Europe for efinaconazole for the treatment of onychomycosis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top